A3160
アセチルサリチル酸
analytical standard
別名:
2-アセトキシ安息香酸, O-アセチルサリチル酸, ASA, アスピリン
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
化学式:
2-(CH3CO2)C6H4CO2H
CAS番号:
分子量:
180.16
UNSPSC Code:
12352106
NACRES:
NA.21
PubChem Substance ID:
EC Number:
200-064-1
Beilstein/REAXYS Number:
779271
MDL number:
製品名
アセチルサリチル酸, analytical standard
InChI key
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
InChI
1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
SMILES string
CC(=O)Oc1ccccc1C(O)=O
grade
analytical standard
form
powder
packaging
vial of 500 mg
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
mp
134-136 °C (lit.)
application(s)
forensics and toxicology
pharmaceutical
veterinary
Quality Level
Gene Information
human ... ITGA2B(3674), PTGS1(5742), PTGS2(5743)
類似した製品をお探しですか？ 訪問 製品比較ガイド
Biochem/physiol Actions
COX-1アイソフォームに対する向上した選択性で、シクロオキシゲナーゼ（プロスタグランジンH合成酵素）の阻害によりプロスタグランジン産生を遮断。抗血栓作用は、トロンボキサン産生および血小板凝集を抑制する血小板中のCOX-1の阻害によるものです。結腸直腸およびその他の固形腫瘍に対する化学的予防。
Packaging
スクリューキャップ付褐色バイアル入り
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
保管分類
11 - Combustible Solids
wgk
WGK 1
flash_point_f
482.0 °F
flash_point_c
250 °C
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Niels Hulsman et al.
Journal of medicinal chemistry, 50(10), 2424-2431 (2007-04-20)
Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and biologists alike. It consists of ASA and a -ONO2 group connected through a spacer and is in preclinical development as an antitumor drug. We report that, contrary to
Christina Perneby et al.
Thrombosis and haemostasis, 95(4), 652-658 (2006-04-08)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day
Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
A O Maree et al.
Journal of thrombosis and haemostasis : JTH, 3(10), 2340-2345 (2005-09-10)
Aspirin (acetylsalicylic acid) irreversibly inhibits platelet cyclooxygenase (COX)-1, the enzyme that converts arachidonic acid (AA) to the potent platelet agonist thromboxane (TX) A2. Despite clear benefit from aspirin in patients with cardiovascular disease (CAD), evidence of heterogeneity in the way
Gregg W Stone et al.
Lancet (London, England), 382(9892), 614-623 (2013-07-31)
The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）